Key Developments: Agilent Technologies Inc (A.N)

A.N on New York Stock Exchange

57.38USD
27 Aug 2014
Price Change (% chg)

$-0.47 (-0.81%)
Prev Close
$57.85
Open
$58.00
Day's High
$58.00
Day's Low
$57.29
Volume
295,755
Avg. Vol
440,740
52-wk High
$61.21
52-wk Low
$46.39

Search Stocks

Latest Key Developments (Source: Significant Developments)

CORRECTION OFFICIAL - Agilent Technologies Inc announces cash dividend
Tuesday, 1 Apr 2014 01:36pm EDT 

CORRECTED TO READ - "quarterly dividend of $0.132 per share"... INSTEAD OF ... "quarterly dividend of $0.13 per share"... IN THE BODY.Agilent Technologies Inc:Declares quarterly dividend of $0.132 per share.Payable on April 23 to all shareholders of record as of the close of business on April 11.  Full Article

Genetic Technologies Ltd announces that Californian court denies motion to dismiss, brought by Agilent Technologies Inc
Tuesday, 11 Mar 2014 06:03pm EDT 

Genetic Technologies Ltd:Says that the United States District Court for Northern District of California has last week issued an order denying a motion brought by Agilent Technologies Inc, to dismiss the patent infringement law suit brought against it by GTG.Action was initially brought by GTG against Agilent in 2011, in the District Court of Colorado, but was then moved at request of Agilent to District Court in Northern District of California.Thereafter, both sides filed motions in support of their different legal perspectives.Most recently, Agilent moved to have GTG's complaint dismissed, arguing the relevant GTG patent covers natural phenomena or laws of nature that are not entitled to patent protection, and that court should therefore dismiss action.On March 9, the court issued order denying Agilent's motion to dismiss.  Full Article

Agilent Technologies Inc introduces Handheld FTIR Spectrometer
Monday, 3 Mar 2014 11:00am EST 

Agilent Technologies Inc:Introduces a mobile spectroscopy product that is ideal for on-site testing in a broad range of applications, including advanced materials, art, historical objects, geology, agriculture, composites, coatings and polymers.  Full Article

Agilent Technologies Inc and CambTEK to provide combined solution for liquid chromatography
Monday, 24 Feb 2014 11:00am EST 

Agilent Technologies Inc and CambTEK Ltd:Says agreement to co-market CambTEK's Rapid Extraction System (RES) automated sample preparation technology with an assortment of Agilent's liquid phase separation, life science and chemical analysis instruments and software.Used together, these laboratory solutions provide analytical researchers in the pharmaceutical, chemical and food industries with powerful tools to increase the speed and efficiency of laboratory workflows and maximize the quality of their results.  Full Article

Agilent Technologies Inc announces new study reinforces major advantages of Dako's HER2 IQFISH pharmDx in Breast Cancer Diagnostics
Friday, 14 Feb 2014 09:11am EST 

Agilent Technologies Inc:Says positive findings in an independent French multicenter study on the performance of Dako's HER2 IQFISH pharmDx.Says the Toulouse, France, breast cancer group led by Magali Lacroix-Triki has published a peer-reviewed publication in the Journal of Histopathology.Says that supports the use and performance of Dako's HER2 IQFISH pharmDx for HER2 gene amplification status assessment in breast cancer.Says Dako introduced the cutting-edge IQFISH hybridization buffer chemistry in 2012.Says the IQFISH buffer reduces test turnaround time from 17 hours to just 3.5 hours.Says more than 1.5 mln new cases of breast cancer are diagnosed each year worldwide.Says as an aid in the treatment decision, HER2 IQFISH pharmDx can quantitatively determine HER2 gene amplification in the tumor.Says the study concludes that the highly concordant results (99.3 pct) and assay robustness support IQFISH as a useful alternative to FISH, allowing reliable assessment of HER2 status.Says it also finds that using this method enables pathologists to report the results to the oncologist within a day, meaning patients can begin cancer treatment sooner than ever.  Full Article

Agilent Technologies Inc gives Q2 2014 guidance below analysts' estimates; lowers FY 2014 guidance
Thursday, 13 Feb 2014 04:05pm EST 

Agilent Technologies Inc:Expects Q2 2014 revenues to be in the range of $1.72 billion to $1.74 billion.Expects Q2 2014 non-GAAP earnings to be in the range of $0.71 to $0.73 per share.Expects fiscal 2014 revenue of $6.90 billion to $7.10 billion.Expects fiscal 2014 non-GAAP earnings of $2.96 to $3.16 per share (EPS).Q2 2014 revenues of $1.78 billion and EPS of $0.81 - Thomson Reuters I/B/E/S.FY 2014 revenue of $7.05 billion and EPS of $3.19 - Thomson Reuters I/B/E/S.  Full Article

Agilent Technologies Inc's Dako and Amgen expand collaboration with plan to develop new diagnostic test
Tuesday, 11 Feb 2014 09:03am EST 

Agilent Technologies Inc:Says Dako, an Agilent Technologies company announces a new project with Amgen to develop a molecular diagnostic test using Dako's IQFISH hybridization buffer.Says the cutting-edge IQFISH hybridization buffer, introduced by Dako in 2012, reduces diagnostic test turnaround time from 17 hours to just 3.5 hours.Says it enables pathology labs-for the first time-to run DNA-based hybridization assays quickly, with distinct and higher fluorescent signal intensity compared to traditional FISH assays.Says this ability represents a advance for pathologists, oncologists and ultimately patients.Says companion diagnostics are becoming increasingly important in treating disease.  Full Article

Agilent Technologies Inc Authorizes New Share Repurchase Program And Increases Quarterly Dividend By 10%
Friday, 22 Nov 2013 09:00am EST 

Agilent Technologies Inc announced that its board of directors has authorized a new share repurchase program, effective upon the conclusion of the Company`s existing $1 billion repurchase program. The new repurchase program is designed to reduce or eliminate dilution resulting from issuances of stock under the Company`s employee equity incentive programs to maintain a share count of approximately 335 million diluted shares. The board has also authorized a 10% increase in the quarterly dividend to $0.132 per share. The dividend will be paid on Jan. 22, 2014, to all stockholders of record as of the close of business on Dec. 31, 2013.  Full Article

Agilent Technologies Inc to Collaborate with University of Queensland on Oral Cancer Research
Wednesday, 20 Nov 2013 11:00am EST 

Agilent Technologies Inc announced it will collaborate with the University of Queensland Centre for Clinical Research in Brisbane, Australia, to increase understanding of the genomic differences between young and older patients with oral cancer and between progressive and non-progressive oral potentially malignant lesions.  Full Article

Agilent Technologies Inc Issues Q1 2014 Guidance; EPS Guidance Below Analysts' Estimates; Issues FY 2014 Guidance In Line With Analysts' Estimates
Thursday, 14 Nov 2013 04:05pm EST 

Agilent Technologies Inc announced that for the first quarter of 2014, it expects revenue to be in the range of $1.68 billion to $1.70 billion and non-GAAP earnings are expected to be in the range of $0.65 to $0.67 per share. For fiscal 2014, it expects revenue of $6.95 billion to $7.15 billion and non-GAAP earnings of $3.03 to $3.33 per share. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $1.72 billion and EPS of $0.73 for the first quarter of 2014; revenues of $7.04 billion and EPS of $3.17 for fiscal 2014.  Full Article

Search Stocks